CholestaGel en es it fr

CholestaGel Brand names, CholestaGel Analogs

CholestaGel Brand Names Mixture

  • No information avaliable

CholestaGel Chemical_Formula


CholestaGel RX_link

No information avaliable

CholestaGel fda sheet

CholestaGel msds (material safety sheet)

CholestaGel Synthesis Reference

No information avaliable

CholestaGel Molecular Weight

77.1497 g/mol

CholestaGel Melting Point

98 oC

CholestaGel H2O Solubility

No information avaliable

CholestaGel State


CholestaGel LogP


CholestaGel Dosage Forms

Capsule (50 mg, 150 mg)

CholestaGel Indication

Given intravenously or orally to treat radiation sickness. The bitartrate has been used for the oral treatment of nephropathic cystinosis.

CholestaGel Pharmacology

People born without the ability to metabolize the amino acid cystine suffer from cystinosis, a rare inherited disorder characterized by the deposition and accumulation of cystine crystals throughout the body. These crystals cause considerable damage, particularly in the kidney. Kidney failure can occur by the age of 10 in untreated patients. Cysteamine prevents the accumulation of cystine crystals and is prescribed to prevent further kidney damage. Cysteamine helps to convert cystine into less harmful chemical forms that can be removed from cells.

CholestaGel Absorption

No information avaliable

CholestaGel side effects and Toxicity

Symptoms of overdose may include convulsions (seizures), increased thirst and unusual tiredness or weakness.

CholestaGel Patient Information

No information avaliable

CholestaGel Organisms Affected

Humans and other mammals